Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Phenotypic diversity of human adipose tissue-resident NK cells in obesity

Haugstøyl ME., Cornillet M., Strand K., Stiglund N., Sun D., Lawrence-Archer L.

Laboratory Study on Type 2 Diabetes, published in Front Immunol (2023) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Front Immunol (2023)
Reported sample size
—
Source database
Europe PMC
PMID
36911659
PMCID
PMC9996326
DOI
10.3389/fimmu.2023.1130370
Citations
7

Abstract (original English)

Natural killer (NK) cells have emerged as key mediators of obesity-related adipose tissue inflammation. However, the phenotype of NK cell subsets residing in human adipose tissue are poorly defined, preventing a detailed understanding of their role in metabolic disorders. In this study, we applied multicolor flow cytometry to characterize CD56 bright and CD56 dim NK cells in blood and adipose tissue depots in individuals with obesity and identified surface proteins enriched on adipose tissue-resident CD56 bright NK cells. Particularly, we found that adipose tissue harbored clusters of tissue-resident CD56 bright NK cells signatured by the expression of CD26, CCR5 and CD63, possibly reflecting an adaptation to the microenvironment. Together, our findings provide broad insights into the identity of NK cells in blood and adipose tissue in relation to obesity.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueKiller Cells, NaturalHumansObesityPhenotypeCD56 Antigen

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research